Valsamo Anagnostou MD PhD (She/Her)
Associate Professor of Oncology at The Johns Hopkins University School of Medicine, Director, Molecular Oncology Lab and Thoracic Oncology Biorepository, Co-director, Thoracic Oncology Precision Medicine Center of Excellence, Co-leader, Johns Hopkins Molecular Tumor Board
Join to View Full Profile
4940 Eastern AvenueBaltimore, MD 21224
Phone+1 410-550-0100
Fax+1 410-550-0101
Dr. Anagnostou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a translational cancer investigator who is focusing on large-scale genomic, multi-omic and liquid biopsy
analyses in human cancers. My research is particularly focused on understanding the molecular mechanisms of response and resistance to immunotherapy and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients treated with immunotherapy. My team's long term goal is to transform medical oncology to molecular oncology, where treatment decisions are tailored not only to a baseline genotype but are also informed by real-time dynamics of liquid biopsies.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2013 - 2016
Yale-New Haven Medical CenterResidency, Internal Medicine, 2010 - 2013
University of AthensClass of 2005
Certifications & Licensure
MD State Medical License 2013 - 2026
Clinical Trials
- Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC Start of enrollment: 2020 May 26
- Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection Start of enrollment: 2023 Jan 27
Publications & Presentations
PubMed
- PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetr...Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P Rodgers, James R Eshleman
Non-Coding RNA Research. 2025-06-01 - Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis.Elise F Gray-Gaillard, Ami A Shah, Clifton O Bingham Iii, Jennifer H Elisseeff, Joseph Murray
Arthritis Research & Therapy. 2025-04-01 - A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy.Thomas U Marron, Jason J Luke, Brianna Hoffner, Jane Perlmutter, Connie Szczepanek
Journal for Immunotherapy of Cancer. 2025-03-22
Journal Articles
- Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful ActivityElad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
Press Mentions
Daily Takeaways from the AACR Annual Meeting 2025: Monday, April 28April 28th, 2025- Immunotherapy: Researchers Identify Ways to Help Predict Outcomes for Cancer TreatmentFebruary 14th, 2023
- A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is Associated with Immunotherapy ResponseFebruary 6th, 2023
- Join now to see all
Grant Support
- Matching genotypes with personalized therapies: Development of a decision support infrastructure to augment the value of precision medicineJOHNS HOPKINS UNIVERSITY2023–2026
- Matching genotypes with personalized therapies: Development of a decision support infrastructure to augment the value of precision medicineJOHNS HOPKINS UNIVERSITY2023–2026
- Large-Scale Genetic Analyses of Human CancerJOHNS HOPKINS UNIVERSITY2006–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
